Clinical Trial Update: An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM) [Phase 1, Phase 2]

View source ↗

Summary

Affinia Therapeutics reports an AAV gene therapy candidate, AFTX-201, for BAG3-related dilated cardiomyopathy is in early-phase development (Phase 1/Phase 2) an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy

Drugs mentioned

• AFTX-201

Snippet

Sponsor: Affinia Therapeutics | Conditions: Dilated Cardiomyopathy (DCM), BAG3 Mutation Associated Dilated Cardiomyopathy | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING